Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

The iPhone 16 Pro and iPhone 16 Pro Max are set to be Apple’s top phones for 2024, so it’s reasonable to expect the company will try and make them look as good and premium as possible. Does ...

Video processing specialist Lumagen has unveiled the latest in its Radiance Pro series, the Radiance Pro 4140. Priced below its predecessor, the Radiance Pro 4240-18G, the new model is apparently ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. Update: Follow our Apple 'Glowtime' event live blog to get full coverage of the iPhone 16 ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

The entire Pixel 9 series brings major design changes over the previous generations. Foremost, it’s important to point out that the Pixel 9 series is slightly more diverse than earlier models ...

We put the best camera phones from Google and Xiaomi to the test to see which one takes better images. Andrew is CNET's go-to guy for product coverage and lead photographer for Europe. When not ...

A DSLR in our pockets. That’s what all flagship smartphones are trying to be in this day and age. Be it actual camera hardware chops or computational photography on-device, tech brands are ...

Please verify your email address. For three years now, a small but vocal contingent of Pixel fans across the internet has dared to dream of a pocket-friendly Pixel flagship — a device with all ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.